学术文献-基石药业

临床模式苏州转化医学研究中心产品管线学术文献

Home - 研究开发 - 学术文献

学术文献

临床模式 
苏州转化医学研究中心 
产品管线 
学术文献 

A Phase II Clinical Trial of CS1001 As A Consolidation Therapy In Patients With L ocally Advanced/Un Who Have Not Progressed After Prior Concurrent/Sequential Chemoradiotherapy (GEMSTONE 301)

发表在：2019年美国临床肿瘤学会（ASCO）年会
A Phase la/lb Trial of The Anti-PD-L1 Human Monoclonal Antibody, CS1001, in Patients with Advanced Solid Tumors or Lymphomas

发表在：2019年美国临床肿瘤学会（ASCO）年会
Preliminary Safety, Pharmacokinetics, and Efficacy Results from a Phase I Study of CS1001, an Anti-Programmed Death Ligand-1 Monoclonal Antibody in Patients with Advanced Malignancies (GEMSTONE 101)

发表在：2018年中国临床肿瘤学会（CSCO）年会
Preliminary Safety, Pharmacokinetics and Efficacy Results from a Phase I Study of CS1001, a Fully Human Anti-PD-L1 Monoclonal Antibody in Patients With Advanced Tumors (GEMSTONE 101)

发表在：2018年中国临床肿瘤学会（CSCO）年会
Preliminary Safety, Pharmacokinetics, and Efficacy Results from a Phase I Study of CS1001, an Anti Programmed Death Ligand 1 Monoclonal Antibody in Patients with Advanced Malignancies (GEMSTONE 101)

发表在：2018年欧洲肿瘤内科学会（ESMO）年会
1711 - Preliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors

发表在：2018年欧洲肿瘤内科学会（ESMO）年会

上一页12/12下一页

声明